Response to Scottish Government decision to fund Orkambi and next steps in England

Last month the independent Scottish Medicines Consortium assessed that Vertex’s ‘justification of the treatment’s [Orkambi and Symkevi] costs in relation to its health benefits was not sufficient’: meaning the company was charging an unreasonably high price for its product. Vertex has rejected the health service’s offer, which would give access to the treatment for people […]